News | April 24, 2008

SCAI, ACC Return to Individual Scientific Sessions in 2009

April 25, 2008 - The Society for Cardiovascular Angiography and Interventions (SCAI) and the American College of Cardiology (ACC) will return to the traditional individual meeting formats for both the SCAI Annual Scientific Sessions and i2 Summit in 2009, in response to SCAI members' request for more a intimate meeting.

In 2008, SCAI and ACC partnered to hold the SCAI Annual Scientific Sessions in Partnership with ACCi2 Summit (SCAI-ACCi2), held in conjunction with ACC's Annual Scientific Session in Chicago.

"This year's SCAI-ACCi2 meeting was a strong achievement, particularly in terms of securing increased positive attention for our field,"? said SCAI President Bonnie H. Weiner, M.D. "Yet SCAI's members are enthusiastic about a return to the intimacy of a meeting with a targeted focus on high-level interventional cardiology. We look forward to continuing to look for ways to provide venues to educate both general and interventional cardiology communities so that we may learn from one another and, as always, provide the most optimal care to all cardiology patients."

"The ACC continues to be committed to serving the needs of our interventional members, and we look forward to a successful 2009 ACC i2 Summit that will build upon the success of this meeting over the past three years," said W. Douglas Weaver, president of the ACC. "Our relationship with SCAI remains strong, and we will continue to collaborate on various initiatives including education, guidelines and advocacy."

For more information: www.scai.org and www.acc.org

Related Content

Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Overlay Init